Cargando…

Ramucirumab, A Second-Line Option For Patients With Hepatocellular Carcinoma: A Review Of The Evidence

Hepatocellular carcinoma (HCC) is the most frequent primary liver cancer and predominantly develops in patients with liver cirrhosis. In patients with advanced disease, such as extra-hepatic extension or portal vein involvement, and with intermediate disease unsuitable for locoregional therapies, sy...

Descripción completa

Detalles Bibliográficos
Autores principales:	De Luca, Emmanuele, Marino, Donatella, Di Maio, Massimo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7246316/ https://www.ncbi.nlm.nih.gov/pubmed/32547208 http://dx.doi.org/10.2147/CMAR.S216220

Ejemplares similares

Second-line treatment options in hepatocellular carcinoma
por: Marino, Donatella, et al.
Publicado: (2019)

Factors Contributing to the Prognosis after Second-line Therapy with Ramucirumab in Advanced Hepatocellular Carcinoma
por: Sugimoto, Rie, et al.
Publicado: (2022)

Second-line ramucirumab therapy for advanced hepatocellular carcinoma (REACH): an East Asian and non-East Asian subgroup analysis
por: Park, Joon Oh, et al.
Publicado: (2016)

Ramucirumab in the second-line for patients with hepatocellular carcinoma and elevated alpha-fetoprotein: patient-reported outcomes across two randomised clinical trials
por: Zhu, Andrew X, et al.
Publicado: (2020)

Pattern of progression in advanced hepatocellular carcinoma treated with ramucirumab
por: Reig, Maria, et al.
Publicado: (2020)

Ramucirumab-Induced Hepatocellular Carcinoma Rupture and Gastrointestinal Perforation
por: Haider, Asim, et al.
Publicado: (2021)

Use of ramucirumab for various treatment lines in real-world practice of patients with advanced hepatocellular carcinoma
por: Kanogawa, Naoya, et al.
Publicado: (2023)

Second-Line Treatment Options for Hepatocellular Carcinoma: Current Landscape and Future Direction
por: Pathak, Surabhi, et al.
Publicado: (2021)

Comparative efficacy and safety for second-line treatment with ramucirumab, regorafenib, and cabozantinib in patients with advanced hepatocellular carcinoma progressed on sorafenib treatment: A network meta-analysis
por: Chen, Jianxin, et al.
Publicado: (2021)

Ramucirumab in the second-line treatment of metastatic colorectal cancer: a narrative review of literature from clinical trials
por: Chen, Chou-Pin, et al.
Publicado: (2020)

Second‐line treatment of hepatocellular carcinoma after sorafenib: Characterizing treatments used over the past 10 years and real‐world eligibility for cabozantinib, regorafenib, and ramucirumab
por: Fung, Andrea S., et al.
Publicado: (2020)

Prevalence and profiles of ramucirumab-associated severe ascites in patients with hepatocellular carcinoma
por: Kamachi, Naoki, et al.
Publicado: (2021)

Clinical Evaluation of Ramucirumab for the Treatment of Hepatocellular Carcinoma (HCC): Place in Therapy
por: Choucair, Khalil, et al.
Publicado: (2021)

Retrospective cohort study of nanoparticle albumin-bound paclitaxel plus ramucirumab versus paclitaxel plus ramucirumab as second-line treatment in patients with advanced gastric cancer
por: Okunaka, Mashiro, et al.
Publicado: (2020)

Second-line treatment of advanced hepatocellular carcinoma: Time for more individualized treatment options?
por: Rajappa, Senthil, et al.
Publicado: (2022)

Potential of ramucirumab in treating hepatocellular carcinoma patients with elevated baseline alpha-fetoprotein
por: Gilabert, Marine, et al.
Publicado: (2018)

Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma
por: Harding, James J., et al.
Publicado: (2021)

Role of regorafenib as second-line therapy and landscape of investigational treatment options in advanced hepatocellular carcinoma
por: Trojan, Jörg, et al.
Publicado: (2016)

Sorafenib as second‐line treatment option after failure of lenvatinib in patients with unresectable hepatocellular carcinoma
por: Tomonari, Tetsu, et al.
Publicado: (2020)

Ramucirumab as second-line treatment in Chinese patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib (REACH-2 China): A randomised, multicentre, double-blind study
por: Shao, Guoliang, et al.
Publicado: (2022)

Sequencing of systemic treatment for hepatocellular carcinoma: Second line competitors
por: Piñero, Federico, et al.
Publicado: (2020)

Efficacy and Safety of Ramucirumab in Patients with Unresectable Hepatocellular Carcinoma with Progression after Treatment with Lenvatinib
por: Kasuya, Kayoko, et al.
Publicado: (2020)

Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab
por: Zhu, Andrew X., et al.
Publicado: (2021)

Therapeutic efficacy of ramucirumab after lenvatinib for post-progression treatment of unresectable hepatocellular carcinoma
por: Hiraoka, Atsushi, et al.
Publicado: (2020)

Exposure–response relationship of ramucirumab in patients with advanced second-line colorectal cancer: exploratory analysis of the RAISE trial
por: Cohn, Allen Lee, et al.
Publicado: (2017)

Initial Report of Second‐Line FOLFIRI in Combination with Ramucirumab in Advanced Gastroesophageal Adenocarcinomas: A Multi‐Institutional Retrospective Analysis
por: Klempner, Samuel J., et al.
Publicado: (2018)

Cost-Effectiveness of ramucirumab plus paclitaxel as a second-line therapy for advanced gastric or gastro-oesophageal cancer in China
por: Li, Sini, et al.
Publicado: (2020)

Nanoparticle albumin-bound paclitaxel and ramucirumab versus paclitaxel and ramucirumab as second-line chemotherapy for unresectable advanced or recurrent gastric cancer: a multicenter, propensity score-matched analysis (CROSS SELL study)
por: Nakasya, Akio, et al.
Publicado: (2022)

Ramucirumab, another anti-angiogenic agent for metastatic colorectal cancer in second-line setting—its impact on clinical practice
por: Goel, Gaurav, et al.
Publicado: (2015)

Comprehensive molecular characterization of gastric cancer patients from phase II second-line ramucirumab plus paclitaxel therapy trial
por: Kim, Seung Tae, et al.
Publicado: (2021)

Correlation Between Tumor Response and Survival Outcomes in Patients with Advanced Gastric Cancer Receiving Ramucirumab and Paclitaxel as Second-Line Therapy
por: Roviello, Giandomenico, et al.
Publicado: (2022)

Maintenance ramucirumab monotherapy after intolerable toxicities following docetaxel plus ramucirumab
por: Hata, Akito, et al.
Publicado: (2018)

A Case of Advanced Hepatocellular Carcinoma with Partial Response after Continuous Ramucirumab Treatment beyond Radiological Progression
por: Wada, Yoshiyuki, et al.
Publicado: (2020)

Phase II Study of Ramucirumab Plus Irinotecan Combination Therapy as Second-Line Treatment in Patients with Advanced Gastric Cancer: HGCSG1603
por: Kawamoto, Yasuyuki, et al.
Publicado: (2022)

Successful conversion surgery for stage IV gastric cancer with liver metastases after second-line chemotherapy with ramucirumab and paclitaxel: a case report
por: Fukuda, Kosuke, et al.
Publicado: (2022)

Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study
por: Chau, Ian, et al.
Publicado: (2018)

Current Options for Second-Line Systemic Therapy in Metastatic Renal Cell Carcinoma
por: Mitsogiannis, Iraklis C., et al.
Publicado: (2022)

Factors predictive of clinical outcome in advanced hepatocellular carcinoma patients receiving ramucirumab treatment: A real‐world experience
por: Lin, Po‐Ting, et al.
Publicado: (2023)

Impact of docetaxel plus ramucirumab in a second‐line setting after chemoimmunotherapy in patients with non‐small‐cell lung cancer: A retrospective study
por: Ishida, Masaki, et al.
Publicado: (2021)

Effective combined therapy with ramucirumab for advanced pulmonary pleomorphic carcinoma
por: Nishioka, Naoya, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_q7hh5orei0gvm45t51di5o51at